• Menu
  • About Melanoma
    • Melanoma 101
    • Melanoma & Skin of Color
    • Types of Melanoma
    • Melanoma Staging
    • Prevention
    • Early Detection
    • Stories
  • For Patients
    • Screening & Diagnosis
    • Just Diagnosed
    • Treatment Options
    • Clinical Trials
    • Patient Resources
  • Research
    • Research Overview
    • Request for Proposals
    • MRA Grant Awards
    • MRA Grant Mechanisms
    • Scientific Retreat
    • Research Resources
  • News
    • Blog
    • Sign Up for Emails
    • Annual Progress Reports
    • For Press
  • Get Involved
    • Donate
    • Events
    • Fundraise for MRA
    • Honor a Loved One
    • Sponsor a Named Award
    • Corporate Partnerships
    • Workplace Giving
  • About MRA
    • Mission
    • Board of Directors
    • MRA Team
    • Scientific Advisory Panel
    • Grant Review Committee
    • Medical Advisory Panel
    • Dermatology Council
    • Financials
    • Careers
    • Corporate Allies

DONATE
  • Improving AI for People of Color: Diagnosing Melanoma & Other Skin Cancers

    The problem with the existing AI algorithms is that they have been developed using images of moles from light skinned (white) individuals. As a result, they often are not sensitive enough in people with darker skin. Dr. Albert Chiou, young investigator on the L’Oréal Dermatological Beauty Brands-MRA Team Science Award, and his colleagues are working to improve AI, so it can help all people, regardless of skin tone.

    Read More
  • New Research Says Combination Immunotherapy Should be First-Line Therapy for Patients with BRAF-mutant Melanoma

    While all patients with advanced melanoma can be treated with checkpoint immunotherapies, patients with tumors containing the BRAF mutation can also be treated with targeted therapies. However, until now, doctors have had little prospective data to determine which treatment approach should be started first. A new study led by Dr. Michael Atkins provides practice-changing insight.

    Read More
  • What Melanoma Patients Need to Know about Opdualag

    You may have heard of Opdualag, a new therapy that recently earned FDA approval for advanced melanoma. Opdualag, which combines two different immunotherapies into one medicine, is earning attention as an effective – and more easily tolerated – combination therapy.

    Read More
  • Melanoma Clinical Trial Success Story: From Patient Volunteer to No Evidence of Disease

    This Mom of three enrolled in a neoadjuvant clinical trial for Stage 3 melanoma. After two infusions of Opdualag, Shannon underwent a successful surgery where doctors removed all affected lymph nodes and tested them, revealing No Evidence of Disease (NED).

    Read More
  • Find a Clinical Trial

    Melanoma Clinical Trial Finder
  • Get Connected

    Find Support for melanoma
  • Latest Report

    Retreat Report Box 2023
  • Get Involved

    Get Involved with Melanoma Outreach
  • About MRA

    Melanoma video

What's New

01/11/2023 – Pioneering New Treatment Strategies for Melanoma

01/04/2023 – Melanoma Exchange Patient Forum - March 8 - Registration Now Open!

11/29/2022 – More Time, More Research, More Hope: Double your Impact by Donating to MRA Today!

11/15/2022 – Artificial Intelligence & Melanoma Detection: Closing the Gaps

11/11/2022 – From Melanoma Patient to Caregiver

Login

I've lost my password

×
Melanoma Research Alliance

730 15th Street, NW
Washington, DC 20005
(202) 336-8935

info@curemelanoma.org

About Melanoma Research Alliance

As the largest non-profit funder of melanoma research, MRA has dedicated $143 million to date in support of the fight against melanoma.

CFC #14131

Privacy Statement